CVR: 32478980
Secondary names: R2 MEDITALIA A/S, R2 PHARMACTIVE A/S, R2 Group Pharmaceuticals A/S
Caldic Denmark A/S is experiencing a declining revenue trend, with a notable drop from 240.9 million DKK in 2022 to 120.1 million DKK in 2024. Despite this decline, the company has maintained profitability, reporting a profit of 7.7 million DKK in 2024, although this is a decrease from 8.5 million DKK in 2022. The equity position has improved over the years, reaching 61.9 million DKK in 2024, indicating a strengthening balance sheet. However, the significant revenue drop raises concerns about its market position and ability to sustain growth within the pharmaceutical and healthcare wholesale industry.
AI-generated summary
Selskabets formål er at drive handels- og agenturvirksomhed samt anden hermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 120.1 mio. | 7.7 mio. | 83.3 mio. | 61.9 mio. | 10 | |
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Torsten Walz joined the board
Hans Robin Daniel Malmros left the board
Companies in the same industry and area
companydata.dk